128 related articles for article (PubMed ID: 21211830)
21. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
22. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
[TBL] [Abstract][Full Text] [Related]
23. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
Ghaffari A; Peterson N; Khalaj K; Vitkin N; Robinson A; Francis JA; Koti M
Br J Cancer; 2018 Aug; 119(4):440-449. PubMed ID: 30046165
[TBL] [Abstract][Full Text] [Related]
24. Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Lu Z; Wientjes TS; Au JL
Pharm Res; 2005 Jul; 22(7):1069-78. PubMed ID: 16028007
[TBL] [Abstract][Full Text] [Related]
25. Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer.
Anwer K; Kelly FJ; Chu C; Fewell JG; Lewis D; Alvarez RD
Gynecol Oncol; 2013 Oct; 131(1):169-73. PubMed ID: 23863356
[TBL] [Abstract][Full Text] [Related]
26. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival.
Jin H; Yang R; Ross J; Fong S; Carano R; Totpal K; Lawrence D; Zheng Z; Koeppen H; Stern H; Schwall R; Ashkenazi A
Clin Cancer Res; 2008 Dec; 14(23):7733-40. PubMed ID: 19047100
[TBL] [Abstract][Full Text] [Related]
27. Death receptor 5 agonist TRA8 in combination with the bisphosphonate zoledronic acid attenuated the growth of breast cancer metastasis.
Szafran AA; Folks K; Warram J; Chanda D; Wang D; Zinn KR
Cancer Biol Ther; 2009 Jun; 8(12):1109-16. PubMed ID: 19652526
[TBL] [Abstract][Full Text] [Related]
28. The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.
Whitworth JM; Londoño-Joshi AI; Sellers JC; Oliver PJ; Muccio DD; Atigadda VR; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2012 Apr; 125(1):226-30. PubMed ID: 22155260
[TBL] [Abstract][Full Text] [Related]
29. Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.
Zhou L; Wang W; Dicker DT; Humphreys RC; El-Deiry WS
Cancer Biol Ther; 2011 Aug; 12(4):335-48. PubMed ID: 21785270
[TBL] [Abstract][Full Text] [Related]
30. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
31. Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Oliver PG; LoBuglio AF; Zhou T; Forero A; Kim H; Zinn KR; Zhai G; Li Y; Lee CH; Buchsbaum DJ
Breast Cancer Res Treat; 2012 Jun; 133(2):417-26. PubMed ID: 21901385
[TBL] [Abstract][Full Text] [Related]
32. Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
Pokrzywinski R; Secord AA; Havrilesky LJ; Puls LE; Holloway RW; Lewandowski GS; Higgins RV; Nycum LR; Kohler MF; Revicki DA
Gynecol Oncol; 2011 Dec; 123(3):505-10. PubMed ID: 21945310
[TBL] [Abstract][Full Text] [Related]
33. [Docetaxel and ovarian cancer].
Ray-Coquard I
Bull Cancer; 2004 Feb; 91(2):159-65. PubMed ID: 15047455
[TBL] [Abstract][Full Text] [Related]
34. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
35. Noninvasive monitoring of pharmacodynamics and kinetics of a death receptor 5 antibody and its enhanced apoptosis induction in sequential application with doxorubicin.
Weber TG; Pöschinger T; Galbán S; Rehemtulla A; Scheuer W
Neoplasia; 2013 Aug; 15(8):863-74. PubMed ID: 23908588
[TBL] [Abstract][Full Text] [Related]
36. A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes.
Yada A; Yazawa M; Ishida S; Yoshida H; Ichikawa K; Kurakata S; Fujiwara K
Ann Oncol; 2008 Jun; 19(6):1060-7. PubMed ID: 18304965
[TBL] [Abstract][Full Text] [Related]
37. A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Alvarez Secord A; Berchuck A; Higgins RV; Nycum LR; Kohler MF; Puls LE; Holloway RW; Lewandowski GS; Valea FA; Havrilesky LJ
Cancer; 2012 Jul; 118(13):3283-93. PubMed ID: 22072307
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
40. Breast tumor xenografts: diffusion-weighted MR imaging to assess early therapy with novel apoptosis-inducing anti-DR5 antibody.
Kim H; Morgan DE; Zeng H; Grizzle WE; Warram JM; Stockard CR; Wang D; Zinn KR
Radiology; 2008 Sep; 248(3):844-51. PubMed ID: 18710978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
